Statement: None of the 3 patients in cohort 1 of the primary trial experienced any adverse events.
Primary_evidence: Adverse Events 1:   Total: 0/3 (0.00%)   Pericardial effusion 0/3 (0.00%)   Tachycardia 0/3 (0.00%)   Nausea 0/3 (0.00%)   Vomiting 0/3 (0.00%)   Abdominal pain 0/3 (0.00%)   Colitis 0/3 (0.00%)   Diarrhoea 0/3 (0.00%)   Gastritis 0/3 (0.00%)   Ileus 0/3 (0.00%)   Fatigue 0/3 (0.00%)   Pyrexia 0/3 (0.00%)   Pain 0/3 (0.00%)   Hepatic cirrhosis 0/3 (0.00%)   Cellulitis 0/3 (0.00%) Adverse Events 2:   Total: 22/64 (34.38%)   Pericardial effusion 1/64 (1.56%)   Tachycardia 1/64 (1.56%)   Nausea 2/64 (3.13%)   Vomiting 2/64 (3.13%)   Abdominal pain 2/64 (3.13%)   Colitis 1/64 (1.56%)   Diarrhoea 1/64 (1.56%)   Gastritis 1/64 (1.56%)   Ileus 1/64 (1.56%)   Fatigue 1/64 (1.56%)   Pyrexia 1/64 (1.56%)   Pain 1/64 (1.56%)   Hepatic cirrhosis 1/64 (1.56%)   Cellulitis 3/64 (4.69%)